April 11th 2024
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
ODAC Gives Taxol Nod for Node+ Breast Cancer
November 1st 1999SILVER SPRING, Md-The Oncologic Drugs Advisory Committee (ODAC) unanimously recommended that the FDA approve Taxol (paclitaxel for injection, Bristol-Myers Squibb) for use in the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-based combination therapy.
Women With BRCA Mutations at Greater Risk for Recurrence, New Breast Tumors
November 1st 1999For many women under 40 years of age with breast cancer, surgery to remove the cancerous lump and accompanying radiation therapy seem to be the best option for eradicating the disease and preserving the natural breast. However, for women who carry a damaged version of the BRCA1 or BRCA2 gene, thus predisposing them to breast cancer, such treatment may be insufficient. Researchers at Jefferson Medical College have found that these women are at greater risk years later of either relapsing or developing new tumors than are similarly treated women who do not carry one of these genes.
Paclitaxel/Carboplatin Effective, Less Toxic Option for Advanced Ovarian Cancer
October 1st 1999A landmark study showed that a new drug combination-paclitaxel (Taxol) and carboplatin (Paraplatin)-is better for the treatment of advanced ovarian cancer because it is significantly less toxic in patients. The combination also maintained the
September Is Gynecologic Cancer Awareness Month
September 1st 1999The Gynecologic Cancer Foundation, along with the American Hospital Association, has declared September 1999 the first annual Gynecologic Cancer Awareness Month. Each year, 82,000 women in the United States (ie, 1 in every 25 women) are
Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
September 1st 1999Despite a response rate of only 9%, single-agent carboplatin (Paraplatin) produced the best 1-year survival rate with the lowest toxicity in a five-arm Eastern Cooperative Oncology Group study of cisplatin (Platinol)
Doxil Approved for Refractory Metastatic Ovarian Cancer
August 1st 1999ROCKVILLE, Md-Doxil (doxorubicin HCl liposome injection, ALZA Corporation) has won accelerated FDA approval of its supplemental New Drug Application for the treatment of metastatic ovarian cancer refractory to both paclitaxel (Taxol)- and platinum-based chemotherapy regimens. Accelerated approval requires the company to conduct additional research to demonstrate that the drug is associated with clinical benefit. Doxil, a liposomal formulation of doxorubicin, is currently approved for use in AIDS-related Kaposi’s sarcoma.
Surgical Debulking + Paclitaxel-Based Adjuvant Chemo Superior to Previous Ovarian Cancer Therapies
August 1st 1999Since its approval by the FDA in 1992, paclitaxel (Taxol) has been widely used in the treatment of ovarian cancer. Surgical debulking has also been proven to increase survival in women with this disease.
Ethyol Approved to Reduce Xerostomia in Head and Neck Cancer
August 1st 1999ROCKVILLE, Md-The FDA has approved Ethyol (amifostine for injection) as a therapy to decrease the incidence of moderate-to-severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer. The approval came only 2 weeks after the Oncologic Drugs Advisory Committee (ODAC) recommendation.
Studies Suggest New Approaches in Hereditary Ovarian Cancer
July 1st 1999SAN FRANCISCO–Ovarian cancers associated with mutations in the BRCA gene have a different underlying biology than nonhereditary cancers and may respond better to treatments not routinely applied in ovarian cancer, according to a study reported at the 30th Annual Meeting of the Society of Gynecologic Oncologists.
Breast Cancer Survivors Under 50 Years Old Are at High Risk for Ovarian Cancer
July 1st 1999Some factors that lead to the development of breast cancer are similar to those responsible for the development of ovarian cancer, say the authors of a new study. Consequently, women who survive breast cancer, especially those under the age of
Breast Cancer Survivors at Increased Risk for Ovarian Cancer
July 1st 1999SAN FRANCISCO-Women who have survived breast cancer are at increased risk for subsequent ovarian cancer, and this risk is especially high in women diagnosed with breast cancer before age 50 and in African-American, Asian, and Hispanic women, according to data presented at the 30th Annual Meeting of the Society of Gynecologic Oncologists.
Watch for Signs of Depression in Ovarian Cancer Patients
July 1st 1999Depression serious enough to affect daily functioning occurs in one of every five patients who have epithelial ovarian cancer, according to data presented at the 30th Annual Meeting of the Society of Gynecologic Oncologists. Diane Bodurka-Bevers, MD, and her colleagues at the University of Texas M.D. Anderson Cancer Center studied this problem in 275 patients with ovarian cancer.
Better Communication of Breast Cancer Risk Urged
July 1st 1999NEW ORLEANS-When talking with women about their personal risk of developing breast cancer, “terms such as relative risk are not very useful,” Patricia Kelly, PhD, said at the American Society of Breast Disease annual meeting, co-sponsored by the Ochsner Medical Foundation, New Orleans.
Case Studies Show Need for Counseling With Genetic Testing
July 1st 1999BALTIMORE-Physicians must help patients sort through the many diagnostic, predictive, and therapeutic alternatives raised by genetic testing, a trio of genetic specialists from Johns Hopkins said at a meeting on clinical cancer genetics and genetic testing.
Survival Improves in Advanced Ovarian Cancer: SEER Study
July 1st 1999SAN FRANCISCO-Five-year survival was significantly better for women with advanced-stage ovarian cancer diagnosed from 1988 to 1994 than for those diagnosed from 1983 to 1987, according to research presented at the 30th Annual Meeting of the Society of Gynecologic Oncologists. This improvement is thought to be due to increased use of surgical debulking and adjuvant platinum/paclitaxel (Taxol).
Discussing Disease Progression and End-of-Life Decisions
Because most patients now want to know the truth about their diagnosis and prognosis, the ability to discuss the cancer diagnosis, disease recurrence, or treatment failure, and to solicit patients’ views about resuscitation
Study Suggests Short Time Interval for Ovarian Cancer Screening
June 1st 1999PHILADELPHIA-To be effective, the time interval for ovarian cancer screening should be no more than a year, a screening trial of 22,000 postmenopausal women suggests. In this study, 67 women were identified with ovarian cancer. For 28 of these women, ovarian cancer was detected within 1 year of their last CA 125 blood test.
Patient Care Costs of Clinical Trials May Be Less Than Standard Care
June 1st 1999WASHINGTON-Accumulating evidence shows that the additional cost of treating cancer patients in clinical trials vs that of providing standard care is essentially negligible, and, in some instances, treatment on protocol is significantly less expensive, experts said at a congressional briefing sponsored by the National Coalition for Cancer Research.
Commentary (Horowitz): Laparoscopy in Gynecologic Malignancies
June 1st 1999Laparoscopy dates back to 1901 when Kelling inspected a dog’s abdominal cavity with a cystoscope introduced transcutaneously. This technique was subsequently applied to humans in 1923.[1] Jacobaeus, in 1910, developed instruments
Commentary (Spirtos/Eisenkop): Laparoscopy in Gynecologic Malignancies
June 1st 1999Minimally invasive surgery is simply the use of small incisions with specialized equipment to accomplish surgical objectives that would otherwise be completed through larger incisions with conventional equipment. A priority of gyne-cologic oncologists
NCI’s CGAP Seeks to Map Complete Genetics of Cancer
May 1st 1999ALEXANDRIA, Virginia-Genetic alterations very early in the disease process lie at the root of every cancer. Functional genomics, the study of which genes are actually functioning at a given time or stage, affords a “new approach” to fighting cancer, reported Kristina Cole, MD, PhD, a cancer research training fellow at the National Cancer Institute, Bethesda, Maryland.
Multimodal Screening Strategy for Ovarian Cancer
April 1st 1999HOUSTON-A multimodal strategy for screening asymptomatic postmenopausal women for ovarian cancer shows promise of being able to find the disease early and improve survival. Researchers for the Ovarian Cancer Screening Project (OCSP) at St. Bartholomew’s Hospital, London, are testing a strategy combining the tumor marker CA 125 with transvaginal ultrasound and a mathematical instrument called the Risk for Ovarian Cancer Algorithm (ROCA).
Effects of Stress on Immune System Studied in Breast Cancer
April 1st 1999HOUSTON-Stress is an immediate reaction to cancer that generally becomes more intensified during the course of the disease. Barbara L. Andersen, PhD, Department of Psychology, Ohio State University, Columbus, and her colleagues are conducting a study to examine the effects of stress on the immune system in cancer patients.